Arctoris Ltd, a developer of a fully automated drug discovery platform, has opened its new global headquarters and state-of-the-art research and development facility in Oxford, UK. The facility houses the company’s proprietary technology and provides space for its growing commercial and scientific teams to support its research partners. 

The new scientific facility houses the company’s next-gen, fully automated platform that generates reproducible data from biochemical, cell-based and molecular biology assays. According to the company, the rapid turnaround enables shorter cycle times and the robotic platform provides pharma and biopharma companies and academic centers with reproducible drug discovery data through an online portal that streamlines experiment planning, ordering, tracking and data analysis.

Martin-Immanuel Bittner MD DPhil, chief executive officer and co-founder of Arctoris, said, “Investing in new global headquarters and greatly enhanced R&D facility in our home city of Oxford, UK, an internationally-renowned centre of scientific excellence, demonstrates our continued commitment to delivering the highest standards of data available to our partners. This state-of-the-art home for our next-generation robotic platform enables our growing team of experts to provide scientists across the globe with access to reproducible data through a rapid and fully-validated approach to drug discovery.”